CVKD vs HIHO Comparison

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Highway Holdings Ltd manufactures and sells metal, plastic and electronic parts, components, subassemblies and finished products for OEMs and contract manufacturers. Its products are used in photocopiers, laser printers, print cartridges, electrical connectors, electrical circuits and other applications. The Company also offers tooling design and development, metal stamping, screen printing, plastic injection molding, pad printing and electronic assembly of printed circuit boards. It operates through metal stamping and mechanical OEM manufacturing operations and electronic OEM manufacturing operations, with metal stamping and mechanical OEM manufacturing operations generating maximum revenue. The Company generates maximum revenue from Europe.